Selection and Sequencing of Therapy for Metastatic Triple-Negative Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Final results from the Phase III ASCENT study of sacituzumab govitecan versus standard chemotherapy for patients with metastatic triple-negative breast cancer (mTNBC) reported a statistically significant improvement in which of the following outcomes with sacituzumab govitecan?**
   - a. Median progression-free survival (PFS)
   - b. Median overall survival
   - c. Both a and b
   - d. None of the above

2. **In the Phase III ASCENT-04/KEYNOTE-D19 trial, which of the following outcomes was observed for patients who received first-line sacituzumab govitecan and pembrolizumab versus chemotherapy and pembrolizumab for PD-L1-positive mTNBC?**
   - a. Inferior PFS with the sacituzumab/pembrolizumab combination
   - b. A numerical but nonsignificant improvement in median PFS with the sacituzumab/pembrolizumab combination
   - c. Statistically significant improvement in median PFS with the sacituzumab/pembrolizumab combination

3. **Emerging data from the Phase III ASCENT-03 trial indicate that first-line sacituzumab govitecan demonstrated a statistically significant improvement in PFS for which patients with mTNBC?**
   - a. Those who are not candidates for PARP inhibitor therapy
   - b. Those who are not candidates for checkpoint inhibitor therapy
   - c. Those with PD-L1-positive disease

4. **The Phase II PRIMED study evaluating primary prophylactic administration of G-CSF and loperamide demonstrated which outcome with regard to the incidence and severity of sacituzumab govitecan-related neutropenia and diarrhea?**
   - a. No significant reduction in neutropenia or diarrhea with prophylactic measures
   - b. Significant reduction in diarrhea but not in neutropenia with prophylactic measures
   - c. Significant reduction in both neutropenia and diarrhea with prophylactic measures

5. **Sacituzumab tirumotecan is a novel antibody-drug conjugate directed against which cell surface protein?**
   - a. HER2
   - b. Androgen receptor
   - c. TROP2
   - d. DLL3

QIDs 5577, 5578